denosumab + Placebo

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Hand Osteoarthritis

Conditions

Hand Osteoarthritis

Trial Timeline

Mar 1, 2016 → Apr 28, 2021

NCT ID

NCT02771860

About denosumab + Placebo

denosumab + Placebo is a phase 2 stage product being developed by Amgen for Hand Osteoarthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT02771860. Target conditions include Hand Osteoarthritis.

What happened to similar drugs?

1 of 10 similar drugs in Hand Osteoarthritis were approved

Approved (1) Terminated (2) Active (7)

✅clobetasol propionateGSK plcApproved

🔄Lebrikizumab + PlaceboEli LillyPhase 3

🔄Pimecrolimus Cream 1%NovartisPhase 3

🔄tocilizumab + saline solutionRochePhase 3

🔄dupilumab + PlaceboSanofiPhase 3

❌Ruxolitinib cream + VehicleIncytePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02771860	Phase 2	Completed	Mar 1, 2016	Apr 28, 2021	Hand Osteoarthritis
NCT00925600	Phase 3	Completed	Nov 30, 2009	May 12, 2016	Cancer
NCT00890981	Phase 3	Completed	Jul 1, 2009	Aug 1, 2010	Low Bone Mass
NCT00286091	Phase 3	Completed	Jan 24, 2006	Apr 9, 2014	Hormone Refractory Prostate Cancer

Competing Products

17 competing products in Hand Osteoarthritis

See all competitors

Product	Company	Stage	Hype Score
Lebrikizumab + Placebo	Eli Lilly	Phase 3	44
Methylprednisolone Tablet	Johnson & Johnson	Phase 2/3	34
ABT-981 + Placebo for ABT-981	AbbVie	Phase 2	35
Pimecrolimus Cream 1%	Novartis	Phase 3	40
tocilizumab + saline solution	Roche	Phase 3	40
Dupilumab + Placebo	Sanofi	Phase 2	31
dupilumab + Placebo	Sanofi	Phase 3	40
clobetasol propionate	GSK plc	Approved	43
urea 40% cream + fluocinonide 0.05% cream + tazarotene 0.1% cream + bland emollient cream (Udderly smooth® Udder Cream)	Bayer	Phase 2	24
Ruxolitinib cream + Vehicle	Incyte	Phase 3	29
Ruxolitinib cream + Vehicle	Incyte	Phase 2	32
Ruxolitinib	Incyte	Phase 1/2	29
Ruxolitinib cream + Vehicle	Incyte	Phase 3	29
ARQ-252 cream 0.3% + ARQ-252 cream 0.1% + ARQ-252 Vehicle Cream	Arcutis Biotherapeutics	Phase 1/2	26
alitretinoin	Basilea Pharmaceutica	Phase 3	34
alitretinoin	Basilea Pharmaceutica	Phase 3	34
alitretinoin	Basilea Pharmaceutica	Phase 3	34